Dutch Health Care Costs Shock

7 April 1997

Health care expenditures in the Netherlands will be much higher in 1998than was anticipated in September 1996. While at that date it was forecast than an increase of 300 billion guilders would be necessary, estimates of extra spending are now rising as high as 1 billion guilders ($530.6 million).

One of the most difficult areas is home care, Health Minister Els Borst has told parliament. New arrangements introduced on January 1, 1997, are now in total chaos, due to weak management resulting from the many reorganizations in recent years. Other problems include the fact that many advisory committees, which were formerly important but are now defunct, have not been eliminated.

Most importantly, notes the Marketletter's local correspondent, is the feeling that the Health Ministry lacks any vision as to long-term planning. Parliamentarians say that actions by Mrs Borst and her Secretary of State, Mrs E Terpstra, always have to be "repaired;" for example, oral contraceptives were removed from fund reimbursement and then reinstated.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight